Cornea/External Disease News

Business was not supposed to be the topic of my last column of 2022.

The FDA granted orphan drug designation to BRM424 for the treatment of neurotrophic keratitis, according to a press release from Brim Biotechnology.

Patients with ocular monkeypox experienced delays in treatment, prolonged illness, hospitalization and, in one case, significant vision impairment, according to a CDC report.

Look what my Secret Santa brought me!

Despite all our advances, keratoconus remains a major cause of visual disability, even in the developed world.

Cross-linking has been a major advance ever since I started doing it 10 to 15 years ago.

Keratoconus is a personal area of interest. In this commentary, I will share a few of my current thoughts on the management of keratoconus.

Not every hot ophthalmology innovation is built to stand the test of time.

The old, small, failed, penetrating keratoplasty is the bane of my existence.

NEW YORK — Small-aperture IOLs are an important tool for managing patients with challenging eyes, according to an expert at OSN New York.